Novo Nordisk Canada Inc.
41 meetings with public office holders, Jul 23, 2025 to Jul 23, 2026.
207 meetings on record since 2017, their first on record.
Meetings over time
- Jul 2025: 2 meetings, with Shahad Khalladi, Sandenga Yeba, Shahad Khallidi
- Aug 2025: 4 meetings, with Yash Nanda, Matthew Hall, Mathew Hall, Karim Bardeesy
- Sep 2025: 5 meetings, with Manuela Tomic, Lisa Xie, Galen Richardson, Dan Mazier, Mackenzy Metcalfe
- Oct 2025: 8 meetings, with Sonia Sidhu, James Rothwell, Ali Ehsassi, Peter Fragiskatos, Daryl Fridhandler
- Nov 2025: 2 meetings, with Parm Bains, Shahad Khalladi
- Dec 2025: 4 meetings, with Ritu Banerjee, Greg Orencsak, Sarah Lawley, Pamela Aung-Thin, Karim Bardeesy
- Jan 2026: 0 meetings
- Feb 2026: 6 meetings, with Helena Jaczek, Marcus Powlowski, Martin Moen, Manuela Tomic, Karim Bardeesy
- Mar 2026: 4 meetings, with Jacques Ramsay, Roy Karam, Michael Coteau, Nasser Haidar
- Apr 2026: 1 meeting, with Manuela Tomic
- May 2026: 0 meetings
- Jun 2026: 4 meetings, with Dan Mazier, Sonia Sidhu, Mackenzy Metcalfe, Tom Kmiec
- Jul 2026: 1 meeting, with Raquel Dancho
Jul 2025peak 8 in a monthJul 2026
Hover or focus a month to see who was met.
What they lobby about
The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.
Who they met
Liberal12 met · 17 meetings
Conservative4 met · 6 meetings
Not in Arena's member list24 met · 35 meetings
- Sandenga Yeba
- Manuela Tomic
- Ritu Banerjee
- Justine Frame
- Mackenzy Metcalfe
- Nasser Haidar
- Shahad Khalladi
- Annahat Kochhar
- Daryl Fridhandler
- Elizabeth Wong
- Galen Richardson
- Greg Orencsak
- James Rothwell
- Janice Charette
- Lisa Xie
- Martin Moen
- Mathew Hall
- Matthew Hall
- Nora Draper
- Pamela Aung-Thin
- Roy Karam
- Sarah Lawley
- Shahad Khallidi
- Shalene Curtis-Micallef
The 40 most-met of 41 people named in these filings.
House of Commons (19) · Health Canada (HC) (17) · Innovation, Science and Economic Development Canada (ISED) (9) · Privy Council Office (PCO) (3) · Prime Minister's Office (PMO) (3) · Finance Canada (FIN) (2)
In their own words
- Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
- Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
- Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
Meetings from the Commissioner of Lobbying of Canada. Canada does not require lobbyists to disclose what they spend, so there is no lobbying budget to report here — only the meetings they filed.